Daniel R. Vlock
Vorstandsvorsitzender bei ALOPEXX, INC.
Ursprung des Netzwerks ersten Grades von Daniel R. Vlock
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
| Private Company | Biotechnology | 8 | |
| Public Company | Biotechnology | 8 | |
Alopexx Enterprises LLC
 Alopexx Enterprises LLC BiotechnologyHealth Technology Alopexx Enterprises LLC engages in investing and managing health care companies. It develops medical therapies and devices for infectious diseases, oncology, central nervous system, and orphan diseases. The firm commercializes an alternative for the treatment and prevention of staphylococcal and other bacterial infections and animal vaccines. The company was founded by Daniel R. Vlock, Deborah Ramsdell and Christine de los Reyes in 2011 and is headquartered in Concord, MA.
5
| Private Company | Biotechnology | 5 |
Valerion Therapeutics LLC
 Valerion Therapeutics LLC Medical SpecialtiesHealth Technology Valerion Therapeutics LLC develops targeted therapies for orphan genetic diseases. The firm utilizes a proprietary antibody-mediated delivery platform to target therapies to specific tissues via a studied transport pathway. It therapies are based on an intracellular delivery technology platform that takes advantage of tissue targeting via an antibody and intracellular delivery dependent on membrane expression of a nucleoside transporter. The company was founded by Timothy S. Harris and Dustin D. Armstrong in 2007 and is headquartered in Concord, MA.
4
| Holding Company | Medical Specialties | 4 |
Alopexx Vaccines LLC
1
| Private Company | 1 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Daniel R. Vlock
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
| Harvard Medical School | College/University | Doctorate Degree Corporate Officer/Principal Corporate Officer/Principal | |
| PFIZER, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer General Counsel Corporate Officer/Principal | |
| Stanford University | College/University | Graduate Degree Masters Business Admin Undergraduate Degree | |
Enobia Pharma, Inc.
 Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer General Counsel | |
| The Trustees of Columbia University in The City of New York | College/University | Doctorate Degree Graduate Degree | |
Phoenicis Therapeutics, Inc.
 Phoenicis Therapeutics, Inc. BiotechnologyHealth Technology Phoenicis Therapeutics, Inc. is a private company that is focused on developing therapies for rare dermatological disorders. The company is based in Hingham, MA. The company's goal is to improve the lives of those who suffer from these conditions. The CEO of the company is Deborah Ramsdell. | Biotechnology | Director/Board Member Chief Executive Officer | |
MatriSys Bioscience, Inc.
 MatriSys Bioscience, Inc. BiotechnologyHealth Technology MatriSys Bioscience, Inc. engages in the development of biologic therapeutics. It offers therapies for dermatology and skin care conditions including atopic dermatitis, rosacea, psoriasis, acne, and skin infections. The company was founded by Mark S. Wilson and Richard L. Gallo in 2015 and is headquartered in La Jolla, CA. | Biotechnology | Chairman Chief Executive Officer | |
| OPIANT PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| ELI LILLY AND COMPANY | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
US Food & Drug Administration
 US Food & Drug Administration General GovernmentGovernment US Food & Drug Administration operates agencies to protect health and human services. It protects and promotes public health through the control and supervision of food safety, tobacco products, dietary supplements, prescription and over-the-counter pharmaceutical drugs, vaccines, biopharmaceuticals, blood transfusions, medical devices, electromagnetic radiation emitting devices, cosmetics, animal foods and feed and veterinary products. The company was founded by Theodore Roosevelt and Harvey Washington Wiley on 30th June, 1906 and is headquartered in Silver Spring, MD. | General Government | Corporate Officer/Principal | |
| Columbia College (New York) | College/University | Undergraduate Degree | |
| Joseph L. Mailman School of Public Health | College/University | Graduate Degree | |
| REPLIGEN CORPORATION | Pharmaceuticals: Major | Corporate Officer/Principal | |
| Columbia University College of Physicians & Surgeons | College/University | Doctorate Degree | |
AstraZeneca LP
 AstraZeneca LP Pharmaceuticals: MajorHealth Technology Part of AstraZeneca PLC, AstraZeneca LP is a pharmaceutical company that focuses on developing and commercializing prescription drugs for various therapeutic areas. The company is based in Wilmington, DE. | Pharmaceuticals: Major | General Counsel | |
| MERCK & CO., INC. | Pharmaceuticals: Major | General Counsel | |
| OREXIGEN THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
The American Society for Clinical Pharmacology & Therapeutics
 The American Society for Clinical Pharmacology & Therapeutics Miscellaneous Commercial ServicesCommercial Services The American Society for Clinical Pharmacology & Therapeutics is a scientific and professional organization that serves the disciplines of clinical pharmacology and translational medicine. The non-profit company is based in Alexandria, VA. The CEO of the company is Sharon Swan. | Miscellaneous Commercial Services | President | |
| Center for Drug Evaluation & Research | General Government | Corporate Officer/Principal | |
| KARYOPHARM THERAPEUTICS INC. | Pharmaceuticals: Major | Director/Board Member | |
Drug Information Association
 Drug Information Association Miscellaneous Commercial ServicesCommercial Services The Drug Information Association is a non-profit multidisciplinary association that operates to promote health and well-being. The non-profit company is based in Horsham, PA. Marwan Fathallah has been the CEO of the company since 2023. | Miscellaneous Commercial Services | Director/Board Member | |
Accelerating Therapeutics for Opportunities in Medicine
 Accelerating Therapeutics for Opportunities in Medicine Packaged SoftwareTechnology Services Accelerating Therapeutics for Opportunities in Medicine (ATOM) is an American company that focuses on molecular design and modeling programs. The private company works with open-source software and AMPL packages to build models and analyze data. The company collaborates with Lawrence Livermore National Laboratory scientists to fight against COVID-19 by combining artificial intelligence/machine learning, bioinformatics, and supercomputing to help discover drugs. ATOM shares updates about their new partners, technical team members, and presentations on their website. | Packaged Software | Director/Board Member | |
| Medical Dictionary For Regulatory Activities | Corporate Officer/Principal | ||
Aerium Therapeutics, Inc.
 Aerium Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Aerium Therapeutics, Inc. is an American biotechnology company that focuses on epidemic and pandemic preparedness. The company is based in Lausanne and has operations in the United States. The company's mission is to discover and develop antibodies and small molecule antivirals against SARS-CoV-2 and other epidemic and pandemic threats. Aerium Therapeutics has a team of world-class scientists and biotechnology veterans, as well as experienced investors. Aerium's lead assets are monoclonal antibodies that show broad activity against important variants of concern (VOCs) of SARS-CoV-2, including Omicron and its subvariants. The company plans to expand its pipeline to antiviral therapeutics in late 2022 and will broaden its focus to other epidemic and pandemic threats in the future. The CEO of the company is Rajeev Venkayya. | Miscellaneous Commercial Services | Director/Board Member | |
DCPrime BV
 DCPrime BV Pharmaceuticals: MajorHealth Technology DCPrime BV engages in the provision of therapeutic vaccines for the treatment of cancer. It develops whole-cell-based vaccine addressing blood cancers with a high risk of relapse. The company was founded by Ada M. Kruisbeek and Rik J. Scheper in March 2005 and is headquartered in Leiden, the Netherlands. | Pharmaceuticals: Major | Chief Executive Officer | |
| MENDUS AB | Biotechnology | Chief Executive Officer | |
Synerkine Pharma BV
 Synerkine Pharma BV Miscellaneous Commercial ServicesCommercial Services Synerkine Pharma BV focuses on developing novel fusion proteins for the treatment of inflammatory, neuropathic and osteoarthritic pain. The company was founded by Hans Preusting in 2018 and is headquartered in Utrecht, Netherlands. | Miscellaneous Commercial Services | Director/Board Member | |
| Bioentrepreneur BV | Founder | ||
Medpharmgene, Inc.
 Medpharmgene, Inc. Miscellaneous Commercial ServicesCommercial Services Medpharmgene, Inc. provides commercial physical research services. The private company is based in Montréal, Canada and was founded in 2001. | Miscellaneous Commercial Services | Director/Board Member | |
Isarna Therapeutics BV
 Isarna Therapeutics BV Financial ConglomeratesFinance Isarna Therapeutics BV is an investment holding Dutch company. The private company is based in Zevenbergen, Netherlands. | Financial Conglomerates | Chief Executive Officer | |
| Cognisense | Director/Board Member | ||
Hoffmann-La Roche, Inc.
 Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Biotechnology | Corporate Officer/Principal | |
| State University of New York at Buffalo | College/University | Doctorate Degree | |
| California State University-Los Angeles | College/University | Corporate Officer/Principal | |
Pharmaceutical Research & Manufacturers of America
 Pharmaceutical Research & Manufacturers of America Pharmaceuticals: MajorHealth Technology Pharmaceutical Research & Manufacturers of America provides pharmaceutical research and biotechnology services. It represents the country’s biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. The company was founded in 1958 and is headquartered Washington, DC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| Columbia College (California) | College/University | Undergraduate Degree | |
Regenacy Pharmaceuticals LLC
 Regenacy Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Regenacy Pharmaceuticals LLC operates as a clinical-stage biopharmaceutical company. It develops treatments for diabetic and peripheral neuropathies. The firm provides treatments through regeneration of normal protein function using oral, isoform selective histone deacetylase enzyme inhibitors. It provides treatment for diseases such as sickle cell disease, ß-thalassemia, leukemia, and cognitive dysfunction in neurological disorders. The company was founded by Marc A. Cohen in December 2016 and is headquartered in Waltham, MA. | Pharmaceuticals: Major | Director/Board Member | |
Deck Therapeutics, Inc.
 Deck Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Deck Therapeutics, Inc. is an American acute omega-3 fatty acid therapeutics development company. Søren Weis Dahl has been the CEO of the company since 2020. | Pharmaceuticals: Major | Director/Board Member | |
Agency For Science Technology & Research Ventures
 Agency For Science Technology & Research Ventures Investment ManagersFinance Agency For Science Technology & Research Ventures is a Venture Capital firm, a subsidiary of Agency for Science, Technology & Research founded in 1991 with headquartered in Singapore. | Investment Managers | Director/Board Member | |
| BELLUS HEALTH | Pharmaceuticals: Major | Corporate Officer/Principal | |
Servier Canada, Inc.
 Servier Canada, Inc. Pharmaceuticals: MajorHealth Technology Servier Canada, Inc. provides healthcare services. It manufactures pharmaceuticals for cardiology, diabetes, depression, venous disease and menopause. The company was founded in 1978 and is headquartered in Quebec, Canada. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| Cite Des Biotechs De Laval | Director/Board Member | ||
Ambrilia Biopharma, Inc.
 Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | Pharmaceuticals: Major | Chief Executive Officer | |
| Université François-Rabelais de Tours | College/University | Doctorate Degree |
Statistik
International
| Vereinigte Staaten | 34 |
| Kanada | 7 |
| Niederlande | 7 |
| Frankreich | 3 |
| Schweden | 2 |
Sektoral
| Health Technology | 24 |
| Consumer Services | 12 |
| Commercial Services | 6 |
| Finance | 5 |
| Government | 3 |
Operativ
| Director/Board Member | 113 |
| Corporate Officer/Principal | 51 |
| Independent Dir/Board Member | 32 |
| Undergraduate Degree | 21 |
| President | 20 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| Richard Cohen | 40 |
| Magda Marquet | 30 |
| Peter Werth | 24 |
| William Chin | 21 |
| Peter Honig | 20 |
| Philippe Calais | 18 |
| Gail H. Cassell | 13 |
| Christine de los Reyes | 12 |
| Deborah Ramsdell | 11 |
| Ann MacDougall | 11 |
| Thomas T. Thomas | 11 |
| Hal Landy | 7 |
| Erik Manting | 7 |
| Susan Duggan | 6 |
| Gerald B. Pier | 5 |
- Börse
- Insiders
- Daniel R. Vlock
- Unternehmensverbindungen